249 related articles for article (PubMed ID: 28148783)
1. Beta-Propiolactone Inactivation of Coxsackievirus A16 Induces Structural Alteration and Surface Modification of Viral Capsids.
Fan C; Ye X; Ku Z; Kong L; Liu Q; Xu C; Cong Y; Huang Z
J Virol; 2017 Apr; 91(8):. PubMed ID: 28148783
[TBL] [Abstract][Full Text] [Related]
2. A 3.0-Angstrom Resolution Cryo-Electron Microscopy Structure and Antigenic Sites of Coxsackievirus A6-Like Particles.
Chen J; Zhang C; Zhou Y; Zhang X; Shen C; Ye X; Jiang W; Huang Z; Cong Y
J Virol; 2018 Jan; 92(2):. PubMed ID: 29093091
[TBL] [Abstract][Full Text] [Related]
3. Treatment of influenza virus with beta-propiolactone alters viral membrane fusion.
Bonnafous P; Nicolaï MC; Taveau JC; Chevalier M; Barrière F; Medina J; Le Bihan O; Adam O; Ronzon F; Lambert O
Biochim Biophys Acta; 2014 Jan; 1838(1 Pt B):355-63. PubMed ID: 24140008
[TBL] [Abstract][Full Text] [Related]
4. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
5. Structures of Coxsackievirus A16 Capsids with Native Antigenicity: Implications for Particle Expansion, Receptor Binding, and Immunogenicity.
Ren J; Wang X; Zhu L; Hu Z; Gao Q; Yang P; Li X; Wang J; Shen X; Fry EE; Rao Z; Stuart DI
J Virol; 2015 Oct; 89(20):10500-11. PubMed ID: 26269176
[TBL] [Abstract][Full Text] [Related]
6. The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems.
Qi An W; Guo Su Z; Wen Pan R; Ping Yang B; Chao Zhang Y; Shi L; Li Q
Hum Vaccin Immunother; 2014; 10(3):628-39. PubMed ID: 24401488
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of antibody neutralization of coxsackievirus A16.
Zhang C; Liu C; Shi J; Wang Y; Xu C; Ye X; Liu Q; Li X; Qiao W; Yin Y; Cong Y; Huang Z
Nat Commun; 2022 Dec; 13(1):7854. PubMed ID: 36543790
[TBL] [Abstract][Full Text] [Related]
8. Identification of Antibodies with Non-overlapping Neutralization Sites that Target Coxsackievirus A16.
He M; Xu L; Zheng Q; Zhu R; Yin Z; Zha Z; Lin Y; Yang L; Huang Y; Ye X; Li S; Hou W; Wu Y; Han J; Liu D; Li Z; Chen Z; Yu H; Que Y; Wang Y; Yan X; Zhang J; Gu Y; Zhou ZH; Cheng T; Li S; Xia N
Cell Host Microbe; 2020 Feb; 27(2):249-261.e5. PubMed ID: 32027857
[TBL] [Abstract][Full Text] [Related]
9. Effects of Three Types of Inactivation Agents on the Antibody Response and Immune Protection of Inactivated IHNV Vaccine in Rainbow Trout.
Tang L; Kang H; Duan K; Guo M; Lian G; Wu Y; Li Y; Gao S; Jiang Y; Yin J; Liu M
Viral Immunol; 2016 Sep; 29(7):430-5. PubMed ID: 27548006
[TBL] [Abstract][Full Text] [Related]
10. Analysis of the beta-propiolactone sensitivity and optimization of inactivation methods for human influenza H3N2 virus.
Sasaki Y; Yoshino N; Sato S; Muraki Y
J Virol Methods; 2016 Sep; 235():105-111. PubMed ID: 27142111
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of SARS-CoV-2 by β-propiolactone causes aggregation of viral particles and loss of antigenic potential.
Gupta D; Parthasarathy H; Sah V; Tandel D; Vedagiri D; Reddy S; Harshan KH
Virus Res; 2021 Nov; 305():198555. PubMed ID: 34487766
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of different inactivation methods for high and low pathogenic avian influenza viruses in egg-fluids for antigen preparation.
Pawar SD; Murtadak VB; Kale SD; Shinde PV; Parkhi SS
J Virol Methods; 2015 Sep; 222():28-33. PubMed ID: 25997377
[TBL] [Abstract][Full Text] [Related]
13. Validation of betapropiolactone (BPL) as an inactivant for infectious bovine rhinotracheitis (IBR) virus.
Kamaraj G; Lakshmi Narasu M; Srinivasan VA
Res Vet Sci; 2008 Dec; 85(3):589-94. PubMed ID: 18262212
[TBL] [Abstract][Full Text] [Related]
14. Cryo-EM structures reveal the molecular basis of receptor-initiated coxsackievirus uncoating.
Xu L; Zheng Q; Zhu R; Yin Z; Yu H; Lin Y; Wu Y; He M; Huang Y; Jiang Y; Sun H; Zha Z; Yang H; Huang Q; Zhang D; Chen Z; Ye X; Han J; Yang L; Liu C; Que Y; Fang M; Gu Y; Zhang J; Luo W; Zhou ZH; Li S; Cheng T; Xia N
Cell Host Microbe; 2021 Mar; 29(3):448-462.e5. PubMed ID: 33539764
[TBL] [Abstract][Full Text] [Related]
15. Cryo-electron microscopy and image classification reveal the existence and structure of the coxsackievirus A6 virion.
Büttner CR; Spurný R; Füzik T; Plevka P
Commun Biol; 2022 Sep; 5(1):898. PubMed ID: 36056184
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of DNA by beta-propiolactone.
Perrin P; Morgeaux S
Biologicals; 1995 Sep; 23(3):207-11. PubMed ID: 8527119
[TBL] [Abstract][Full Text] [Related]
17. A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment.
Lee H; Brendle SA; Bywaters SM; Guan J; Ashley RE; Yoder JD; Makhov AM; Conway JF; Christensen ND; Hafenstein S
J Virol; 2015 Jan; 89(2):1428-38. PubMed ID: 25392224
[TBL] [Abstract][Full Text] [Related]
18. Structural Studies Reveal that Endosomal Cations Promote Formation of Infectious Coxsackievirus A9 A-Particles, Facilitating RNA and VP4 Release.
Domanska A; Plavec Z; Ruokolainen V; Löflund B; Marjomäki V; Butcher SJ
J Virol; 2022 Dec; 96(24):e0136722. PubMed ID: 36448797
[TBL] [Abstract][Full Text] [Related]
19. Coxsackievirus A16 utilizes cell surface heparan sulfate glycosaminoglycans as its attachment receptor.
Zhang X; Shi J; Ye X; Ku Z; Zhang C; Liu Q; Huang Z
Emerg Microbes Infect; 2017 Jul; 6(7):e65. PubMed ID: 28745308
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
